Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO Brad Hauser will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. Management will also conduct one-on-one meetings with qualified investors. The presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website.

THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (autonomix.com). The webcast replay will be archived for 90 days following the event.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

When is Autonomix Medical (AMIX) presenting at the H.C. Wainwright Conference?

Autonomix Medical will present at the conference between September 8-10, 2025 in New York, with the video webcast available starting September 8 at 7:00 AM ET.

How can investors access the Autonomix Medical (AMIX) H.C. Wainwright conference presentation?

The presentation will be available as a video webcast on the Events page in the Investors section of Autonomix's website (autonomix.com) for 90 days following the event.

Who will represent Autonomix Medical (AMIX) at the H.C. Wainwright conference?

Brad Hauser, Chief Executive Officer of Autonomix Medical, will present at the conference.

Will Autonomix Medical (AMIX) management be available for meetings at the conference?

Yes, management will be available for in-person one-on-one meetings with qualified members of the investor community who are registered for the conference.